Etude de l'inhibition fonctionnelle du facteur de transcription HOXA9 ...
Le traitement des leucémies aiguës myéloïdes (LAM) repose encore principalement sur la chimiothérapie conventionnelle alliant aracytine ...
INVESTIGATING A NOVEL GAMMA DELTA (??) T CELL-BASED ...Despite impressive outcomes for Chimeric Antigen Receptor (CAR) therapy in haematological cancers, little progress has so far been made for solid tumours. This. p300/CBP degradation is required to disable the active AR ... - bioRxivIn vivo experiments using an orally active p300/CBP proteolysis targeting chimera (PROTAC) degrader (CBPD-409) showed that p300/CBP ... CAR T cell engineering impacts antigen-independent activationPhosphorylation- dependent regulation of T-cell activation by PAG/Cbp, a lipid raft-associated transmembrane adaptor. Mol Cell Biol. 2003;23 ...
Autres Cours:
